Soleno Therapeutics(US:SLNO) Prnewswireยท2025-09-05 18:49Core Viewpoint - Rosen Law Firm is investigating potential securities claims on behalf of shareholders of Soleno Therapeutics, Inc. due to allegations of materially misleading business information issued to the investing public [1]. Group 1: Company Overview - Soleno Therapeutics, Inc. is facing scrutiny following a short report from Scorpion Capital that raised concerns about its recently approved treatment for Prader-Willi syndrome, VYKAT XR [4]. - The stock price of Soleno Therapeutics fell by 7.4% on August 15, 2025, and further declined by 4.9% on the subsequent trading day [4]. Group 2: Legal Actions - Rosen Law Firm is preparing a class action lawsuit seeking recovery of investor losses for those who purchased Soleno Therapeutics securities, with no out-of-pocket fees or costs for participants [2]. - Investors interested in joining the class action can submit their information through the Rosen Law Firm's website or contact them directly [3]. Group 3: Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements and recognition in the field, including being ranked No. 1 by ISS Securities Class Action Services in 2017 [5]. - The firm has recovered hundreds of millions of dollars for investors, with over $438 million secured in 2019 alone [5].